frameshift mutation in the pncA gene of M. tuberculosis (c.85_86insG). Given the uncertain impact of this mutation, we went on to consider whether computational analysis of protein structure (5) could provide insight into the potential efficacy of PZA.
Methods
We have developed an in silico mutational analysis platform that is able to characterize the molecular consequences of mutations on protein structure and function (5) . This has been used to preemptively identify likely resistance mutations in drug targets (6, 7) . Using these tools, we assessed the biophysical changes on mutation on the structure of PncA and drug activation.
A list of 617 nonsynonymous single-nucleotide variants (nsSNVs) of pncA was obtained from the GMTV (Genome-wide Mycobacterium tuberculosis Variation) Database Project, Tuberculosis Drug Resistance Mutation Database, and saturation mutagenesis (8) . Mapping nsSNVs associated with resistance onto the crystal structure of PncA revealed that they were distributed throughout the entire protein structure ( Figure 1A ), complicating resistance inference from sequence analysis. The structural and functional effects of these mutations were assessed using our graphbased signature pipeline (5) . This provided insight into how the curated nsSNVs altered protein folding, stability, conformation, and PZA-binding affinity. This information was used to train a Random Forest (machine-learning algorithm) binary classifier, using the Weka toolkit. Random Forest is an ensemble-learning robust classification algorithm, in which multiple decision trees are included over a random subset of features and decide the output via majority voting. The model was trained by 10-fold cross-validation and performance evaluated by area under the receiver operating characteristic curve, precision, and accuracy. Further validation of the models was performed using two subsets of 93 mutations, which were nonredundant at the position-level mutations in the training set. Analysis of the final model revealed a set of structural features that distinguished between susceptible and resistant pncA point mutations.
Building on this structural analysis, the functional consequence of the novel clinical frameshift mutation was analyzed in the context of the protein structure. The experimental crystal structure of holo-wild-type PncA (PDB ID: 3PL1) (9) was minimized in Prime, and PZA docked into the active site using Glide, two exclusive packages of the comprehensive homology modeling software Schrödinger Suites. The docking revealed that PZA formed key interactions within the pocket, including with the catalytic triad (Asp8, Lys96, and Cys138), substrate-binding residues (Trp68 and Phe13), and the iron center (Asp49, His51, His57, and Fe 21 ) (10). The wild-type and mutant protein sequences were manually aligned and displayed with ESPript 3.0 (Figure 2A) , and the structure of the mutant ( Figure 2C ) was generated by homology and ab initio modeling, using the experimental structure of the wild type ( Figure  2B ) (Schrödinger Suites).
Results
Using the structural and biophysical effects of the mutations on the protein structure, we were able to classify mutations as either susceptible or resistant with an accuracy of 77% ( Figure 1C ). This approach performed equally well in the identification of either class, correctly classifying all mutations previously associated with conferring PZA resistance at high confidence, and mutations not involved in PZA resistance (100% accuracy) (11) . Strain-specific differences in variants with conflicting experimental data (12) could be detected by our tool, using homology models of the corresponding strain's PncA protein.
Analysis of our model revealed that PncA-resistant mutations were associated with large changes in protein folding and stability (mCSM-Stability scores > 21.72 kcal/mol) (P , 0.0001) or located in close proximity to the catalytic triad and substrate-binding site (,8.54Å) (P , 0.0001). Therefore, these freely available biophysical measurements could provide useful information to help guide genomic analysis of novel pncA variants.
We next considered the patient's frameshift mutation in light of these structural insights. As shown in Figure 2 , the frameshift mutation resulted in the generation of a truncated and incomplete protein that lacked the active site pocket, including most of the catalytic residues and iron coordination residues necessary for activity. This strongly suggests that the pncA c.85_86insG frameshift mutation would lead to a total loss of catalytic activity of the protein, and hence PZA treatment would be completely ineffective in this case, as the mutant PncA could not activate the prodrug. This is reflected in the structure of the mutant protein, which is incomplete and would lack any activity (Figure 2 ). This result was consistent with phenotypic testing, and accordingly, pyrazinamide treatment was ceased.
Discussion
This case study demonstrates the power of using structural information to quantitatively evaluate novel variants in real time, providing invaluable insight to help guide therapy. Although existing recommendations may suggest continuing treatment of multidrugresistant tuberculosis with pyrazinamide irrespective of phenotype testing, our approach suggests that using structural information to guide analysis of genomic sequencing may offer useful tools for clinicians to consider. These structural insights also assist in informing the mechanisms for drug activity and the development of resistance. Our approach is not limited only to analysis of variants in pncA but could be applied to any protein associated with resistance for infectious and noninfectious disease treatment. n 
Overfitting and Use of Mismatched Cohorts in Deep Learning Models: Preventable Design Limitations
To the Editor:
We read with great interest the study by González and colleagues (1) in which they used deep learning models to learn from the computed tomography (CT) scans of 7,983 participants in the COPDGene (Genetic Epidemiology of COPD) study (2) . Their objective was to learn from visual data present in these CT scans and subsequently study the model's ability to diagnose chronic obstructive pulmonary disease (COPD) and predict respiratory events and mortality in a validation cohort (1,000 COPDGene scans) and a test cohort (1, [3] ).
The model performed very well in terms of COPD detection as well as prediction of acute respiratory events in the validation cohort of 1,000 COPDGene participants (i.e., it correctly identified COPD in 773/1,000 scans, and there was a strong correlation between the actual FEV 1 and the predicted FEV 1 [1] ). However, the model's performance in the test cohort was inferior in both detection of COPD and prediction of acute respiratory events (only 29% of individuals were correctly staged, and the model was unable to identify patients at higher risk of respiratory events [1, 4] ).
We believe that there are two significant design limitations in the authors' approach toward execution of the deep learning process and selection of the cohorts.
A significant proportion of the CT scan data (7,983 out of a total of 8,983 COPDGene scans, 88.9%) were used for training the deep learning model (1) . This leads to a potential overfitting of the learning model. Overfitting is the consequence of the model learning from a high volume of details that incorporate both noise and signal existing in the training datasets. This leads to a superior performance in the internal validation cohort and inferior performance in an external test dataset (5) . In other words, such models do not explain test cohorts, but they explain the training data very well (5). This suspicion is supported by the study's superior results in the smaller internal validation cohort and inferior performance in the external test cohort. This is particularly relevant because the validation cohort (n = 1,000 scans, 10% of the COPDGene cohort) likely does not represent most of the variance existing in the COPDGene cohort (a cohort of smokers with and without COPD [2] ).
The second limitation arises as an indirect consequence of inherent differences between the COPDGene and ECLIPSE cohorts. The authors do acknowledge in their discussion that there are significant differences between the validation and test cohorts (1) . In this study, a predominantly GOLD stage 0-1 cohort (1, 2) served as the training set for a model that was tested in a GOLD stage >2 cohort (3). In our opinion, selecting COPDGene scans with established GOLD stages of >2 (representing 36% of the COPDGene cohort [1] , n = 3,600 scans) for teaching and internal validation purposes would have improved the external performance. An ideal deep learning strategy would have allocated 50-70% (n = 1,800-2,500) of these scans to the learning model and the remaining 30-50% scans (n = 1,080-1,800) to the internal validation effort. This would have resulted in a true enumeration of the model's performance in the internal validation phase.
In conclusion, the findings could simply represent the performance of a potentially overfitted model (5) and likely do not reflect the suggested superior performance of the tool in the COPDGene validation dataset. The lack of use of appropriate cohorts for training and validation is another significant limitation and can explain the inferior performance in the test cohort (ECLIPSE). n 
